Preclinical trials on cohorts of wild-type mice challenged with transplantable syngeneic ErbB2+ tumors or mice engineered to develop a specific ErbB2+ carcinomas are used to assess the protective potential of a vaccine and tease apart the mechanisms on which it depends. Here, ERBB2 is linked to carcinoma.